Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers

Frank A Sinicrope, Rafaela L. Rego, Nathan R. Foster, Stephen N Thibodeau, Steven Robert Alberts, Harold E. Windschitl, Daniel J. Sargent

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: Proapoptotic BH3-only proteins Bad and Bid initiate apoptosis by binding to regulatory sites on prosurvival Bcl-2 proteins to directly neutralize their function. We determined if expression of these proteins in colon cancers may account for differences in patient survival. Experimental Design: Tumor-node-metastasis stages II and III primary colon carcinomas from patients treated in 5-fluorouracil-based adjuvant therapy trials were studied. Immunohistochemical analysis of Bad and Bid proteins was done in tumors (n = 379) and adjacent normal mucosa. Expression was correlated with clinicopathologic variables, disease-free survival rates (DFS), and overall survival (OS) rates. Results: High expression of the Bad protein [hazard ratio (HR), 0.64; 95% confidence interval (95% CI), 0.43-0.96; P = 0.031] in the cytoplasm of tumor cells was significantly associated with more favorable OS in a univariate analysis. The combined Bad and Bid variable was prognostic for DFS (P = 0.027) and OS (P = 0.006). Stage and histologic grade, but not DNA mismatch repair status, were also prognostic for OS. Multivariate Cox analysis showed that high expression of Bad (HR, 0.64; 95% CI, 0.43-0.97; P = 0.027) and Bid (HR, 0.68; 95% CI, 0.49-0.97; P = 0.034) were independent predictors of OS after adjustment for stage, grade, age, treatment, and study. The combined variable of Bad + Bid was independently associated with DFS (P = 0.020) and OS (P = 0.004). Conclusion: Proapoptotic Bad and Bid proteins are independent prognostic variables in colon cancer patients receiving adjuvant treatment. If validated, Bad and Bid expression may assist in risk stratification and selection of patients to receive adjuvant chemotherapy.

Original languageEnglish (US)
Pages (from-to)4128-4133
Number of pages6
JournalClinical Cancer Research
Volume14
Issue number13
DOIs
StatePublished - Jul 1 2008

Fingerprint

BH3 Interacting Domain Death Agonist Protein
bcl-Associated Death Protein
Colonic Neoplasms
Survival
Survival Rate
Disease-Free Survival
Confidence Intervals
Neoplasms
DNA Mismatch Repair
Adjuvant Chemotherapy
Fluorouracil
Patient Selection
Colon
Cytoplasm
Mucous Membrane
Proteins
Research Design
Therapeutics
Multivariate Analysis
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. / Sinicrope, Frank A; Rego, Rafaela L.; Foster, Nathan R.; Thibodeau, Stephen N; Alberts, Steven Robert; Windschitl, Harold E.; Sargent, Daniel J.

In: Clinical Cancer Research, Vol. 14, No. 13, 01.07.2008, p. 4128-4133.

Research output: Contribution to journalArticle

Sinicrope, Frank A ; Rego, Rafaela L. ; Foster, Nathan R. ; Thibodeau, Stephen N ; Alberts, Steven Robert ; Windschitl, Harold E. ; Sargent, Daniel J. / Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 13. pp. 4128-4133.
@article{3fc7b9e46c1245eb98b6524a8b3749ed,
title = "Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers",
abstract = "Purpose: Proapoptotic BH3-only proteins Bad and Bid initiate apoptosis by binding to regulatory sites on prosurvival Bcl-2 proteins to directly neutralize their function. We determined if expression of these proteins in colon cancers may account for differences in patient survival. Experimental Design: Tumor-node-metastasis stages II and III primary colon carcinomas from patients treated in 5-fluorouracil-based adjuvant therapy trials were studied. Immunohistochemical analysis of Bad and Bid proteins was done in tumors (n = 379) and adjacent normal mucosa. Expression was correlated with clinicopathologic variables, disease-free survival rates (DFS), and overall survival (OS) rates. Results: High expression of the Bad protein [hazard ratio (HR), 0.64; 95{\%} confidence interval (95{\%} CI), 0.43-0.96; P = 0.031] in the cytoplasm of tumor cells was significantly associated with more favorable OS in a univariate analysis. The combined Bad and Bid variable was prognostic for DFS (P = 0.027) and OS (P = 0.006). Stage and histologic grade, but not DNA mismatch repair status, were also prognostic for OS. Multivariate Cox analysis showed that high expression of Bad (HR, 0.64; 95{\%} CI, 0.43-0.97; P = 0.027) and Bid (HR, 0.68; 95{\%} CI, 0.49-0.97; P = 0.034) were independent predictors of OS after adjustment for stage, grade, age, treatment, and study. The combined variable of Bad + Bid was independently associated with DFS (P = 0.020) and OS (P = 0.004). Conclusion: Proapoptotic Bad and Bid proteins are independent prognostic variables in colon cancer patients receiving adjuvant treatment. If validated, Bad and Bid expression may assist in risk stratification and selection of patients to receive adjuvant chemotherapy.",
author = "Sinicrope, {Frank A} and Rego, {Rafaela L.} and Foster, {Nathan R.} and Thibodeau, {Stephen N} and Alberts, {Steven Robert} and Windschitl, {Harold E.} and Sargent, {Daniel J.}",
year = "2008",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-07-5160",
language = "English (US)",
volume = "14",
pages = "4128--4133",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers

AU - Sinicrope, Frank A

AU - Rego, Rafaela L.

AU - Foster, Nathan R.

AU - Thibodeau, Stephen N

AU - Alberts, Steven Robert

AU - Windschitl, Harold E.

AU - Sargent, Daniel J.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Purpose: Proapoptotic BH3-only proteins Bad and Bid initiate apoptosis by binding to regulatory sites on prosurvival Bcl-2 proteins to directly neutralize their function. We determined if expression of these proteins in colon cancers may account for differences in patient survival. Experimental Design: Tumor-node-metastasis stages II and III primary colon carcinomas from patients treated in 5-fluorouracil-based adjuvant therapy trials were studied. Immunohistochemical analysis of Bad and Bid proteins was done in tumors (n = 379) and adjacent normal mucosa. Expression was correlated with clinicopathologic variables, disease-free survival rates (DFS), and overall survival (OS) rates. Results: High expression of the Bad protein [hazard ratio (HR), 0.64; 95% confidence interval (95% CI), 0.43-0.96; P = 0.031] in the cytoplasm of tumor cells was significantly associated with more favorable OS in a univariate analysis. The combined Bad and Bid variable was prognostic for DFS (P = 0.027) and OS (P = 0.006). Stage and histologic grade, but not DNA mismatch repair status, were also prognostic for OS. Multivariate Cox analysis showed that high expression of Bad (HR, 0.64; 95% CI, 0.43-0.97; P = 0.027) and Bid (HR, 0.68; 95% CI, 0.49-0.97; P = 0.034) were independent predictors of OS after adjustment for stage, grade, age, treatment, and study. The combined variable of Bad + Bid was independently associated with DFS (P = 0.020) and OS (P = 0.004). Conclusion: Proapoptotic Bad and Bid proteins are independent prognostic variables in colon cancer patients receiving adjuvant treatment. If validated, Bad and Bid expression may assist in risk stratification and selection of patients to receive adjuvant chemotherapy.

AB - Purpose: Proapoptotic BH3-only proteins Bad and Bid initiate apoptosis by binding to regulatory sites on prosurvival Bcl-2 proteins to directly neutralize their function. We determined if expression of these proteins in colon cancers may account for differences in patient survival. Experimental Design: Tumor-node-metastasis stages II and III primary colon carcinomas from patients treated in 5-fluorouracil-based adjuvant therapy trials were studied. Immunohistochemical analysis of Bad and Bid proteins was done in tumors (n = 379) and adjacent normal mucosa. Expression was correlated with clinicopathologic variables, disease-free survival rates (DFS), and overall survival (OS) rates. Results: High expression of the Bad protein [hazard ratio (HR), 0.64; 95% confidence interval (95% CI), 0.43-0.96; P = 0.031] in the cytoplasm of tumor cells was significantly associated with more favorable OS in a univariate analysis. The combined Bad and Bid variable was prognostic for DFS (P = 0.027) and OS (P = 0.006). Stage and histologic grade, but not DNA mismatch repair status, were also prognostic for OS. Multivariate Cox analysis showed that high expression of Bad (HR, 0.64; 95% CI, 0.43-0.97; P = 0.027) and Bid (HR, 0.68; 95% CI, 0.49-0.97; P = 0.034) were independent predictors of OS after adjustment for stage, grade, age, treatment, and study. The combined variable of Bad + Bid was independently associated with DFS (P = 0.020) and OS (P = 0.004). Conclusion: Proapoptotic Bad and Bid proteins are independent prognostic variables in colon cancer patients receiving adjuvant treatment. If validated, Bad and Bid expression may assist in risk stratification and selection of patients to receive adjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=48249116801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249116801&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-5160

DO - 10.1158/1078-0432.CCR-07-5160

M3 - Article

C2 - 18593990

AN - SCOPUS:48249116801

VL - 14

SP - 4128

EP - 4133

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -